Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piramal Enterprises Ltd.

www.piramal.com

Latest From Piramal Enterprises Ltd.

Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma

Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Deals India

Piramal To Plant A Flag In North America

Indian contract development and manufacturing organization Piramal Pharma Solutions is to bolster its manufacturing capabilities after agreeing to acquire a site from US-based G&W Laboratories, with plans to offer high-potency drug manufacturing capabilities in the future.

Deals Manufacturing

Piramal Pharma Stake Sale On Track

Piramal Enterprises, which is in the process of fundraising for its pharma business, says it is well geared to cater to evolving requirements in the sector amid COVID-19 given its global manufacturing footprint with a strong compliance record. Pharma, the Indian firm’s management maintains, is one of the ‘safest and most resilient’ industries in the current uncertainty.

Commercial Coronavirus COVID-19

Amneal And Amgen Dealt Same Sensipar Fate

Generics players circled around Amgen’s $1.4bn Sensipar brand, filing ANDA products they believed did not meet the claim limitations of the originator’s formulation patent expiring in 2026. A US Court of Appeals handed out a mixed judgment in January this year, leading Amgen and ANDA filer Amneal to petition their respective decisions for rehearings, which have now received a response.

Legal Issues Intellectual Property
See All

Company Information

  • Industry
  • Diversified
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Piramal Healthcare Ltd.
  • Nicholas Piramal India Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Piramal Enterprises Ltd.
  • Senior Management
  • Vivek Sharma, CEO, Pharma Solutions
    Rajesh Laddha, CFO
    Ajay G Piramal, Chmn.
    Vijay Shah, COO
  • Contact Info
  • Piramal Enterprises Ltd.
    Phone: (91) 22 309566666
    247 Business Pk, LBS Marg, Vikhroli (W)
    A Wing, 6th Fl.
    Mumbai, Maharashtra, 400083
    India
UsernamePublicRestriction

Register